Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. - Wikidata - wikimedia - TriplyDB

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

http://www.wikidata.org/entity/Q44452165

about

Invariant NKT cells as novel targets for immunotherapy in solid tumors Antitumor Responses of Invariant Natural Killer T Cells CD1d- and MR1-Restricted T Cells in Sepsis Adoptive T Cell Therapy Targeting CD1 and MR1 The regulatory role of invariant NKT cells in tumor immunity iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis.Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency Bioinformatics multivariate analysis determined a set of phase-specific biomarker candidates in a novel mouse model for viral myocarditis.Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1 Recognition of lipid antigens by T cells.Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans Invariant NKT cells increase drug-induced osteosarcoma cell death.NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells.Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.NKT cell costimulation: experimental progress and therapeutic promise The adaptor molecule SAP plays essential roles during invariant NKT cell cytotoxicity and lytic synapse formation.Roles of CD1d-restricted NKT cells in the intestine.Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges.Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine.NKT cells in mucosal immunity.Targeting natural killer cells and natural killer T cells in cancer.Natural killer T cell based Immunotherapy.Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice Natural killer T cells in liver injury, inflammation and cancer.A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies.

P2860

Q21284987-82F65F4D-E2DE-4DBA-999B-CC78869CE167 Q26778648-DDC068D1-4E78-45D9-A2BA-5841D7434B56 Q26796132-0186F866-EDAF-41D5-A398-9FC756A0F401 Q26998503-DD235162-BD1A-4D85-9BCB-2D0093974DE8 Q27023425-74B8A171-1E9A-4A7E-9A77-F2D46F2CBB8E Q33523809-89807C9D-EAF2-446A-9685-833E16B71A92 Q33622444-9CA96E83-33AE-4F6B-8C55-C5D2EE556BBB Q33939552-EFE387DD-6F4E-45C1-BDD9-863BCA058B39 Q34257912-1101DA74-B45A-4E1A-84B0-D47B882732D6 Q34338958-E609CD5E-B88F-461F-8458-323825A07CC7 Q35096144-A7057ED4-AE63-4530-A271-323BAFF6838C Q35127172-1668EF6F-5F37-4B68-BC39-DBED3FD6EAB0 Q35136030-9B1D30BB-A375-42AE-890F-DAC14F155E6B Q35506478-9DAB488B-51EE-4F15-805E-6401B8A4DEE1 Q35605318-55E8388F-283B-4635-8B95-4665E203E295 Q35956535-291D27E0-D499-4993-9D39-C1C8076E9E38 Q35990678-B1A348E3-68A8-4D4E-9ACD-53F49CD0A561 Q36012693-3F30C5F7-8AC3-41F2-B52B-E7C46E75B6FC Q36146922-9B8D2CB5-CB1C-48BA-BA16-5227786EC949 Q36177081-7D40FF2C-EF9A-46BB-915A-48DE6E9EBB23 Q36239694-C2B27C62-B574-4C17-908A-C2F066EE89F4 Q36446525-8FA23DA4-BE4D-4B23-AFB6-CD1838B94245 Q36568780-7A4E5743-B3B2-410E-9F10-976C46F49184 Q36570136-46ADCC02-0E5A-4278-96FB-191E39EB7C15 Q36713547-76FC44D8-D4CA-4146-B835-EB17A18A4500 Q36739843-2DD220A3-5D40-4645-81DD-DE6ABE9BF1FE Q36797263-DA20BD9F-923C-4B36-BD3B-010BFCD961FA Q36809882-138581D9-E1DA-4E61-8A0C-27A99F6EA377 Q37121488-ED6A1997-741B-4E62-AE85-4C6F84FCD162 Q37209184-F796E2F3-6D77-4E95-A6AE-0910E8D82FDF Q37246757-C530B9B9-C20C-4032-B08A-685B6BF1A447 Q37257512-96AF74DB-ED16-47FE-9AF7-284D541C22B8 Q37388427-339256F5-5606-414E-84F7-657D4A335C8B Q37426935-25529321-2CB9-4F54-B761-5D27A3C9C1F1 Q37545348-832A2736-76B5-47AD-9A7F-469587B0D547 Q37995950-97899AFE-8727-4FAD-9F56-316CF91BB4E4 Q38148759-D07A1E43-D1B3-4D93-B33E-E0DCCD5BEB44 Q38338690-82FCFAB1-5564-4224-A1EE-F08D28C44EFA Q38525797-90967A36-FA3E-4BE6-A191-EA8B82C6C155 Q38634685-E82A2347-1F7F-4892-85D1-036A1A8916CC

P2860

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

http://www.wikidata.org/entity/Q44452165

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

@en

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

@nl

type

label

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

@en

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

@nl

prefLabel

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

@en

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

@nl

P1433

Q44452165-24FE45E6-4D59-459B-8930-3A612CEF894D

P1476

Q44452165-64054A47-6964-411D-AC91-09EB133E0DDF

P2093

Q44452165-1D5DBA04-181C-4935-B3C0-4B47D0E904BC

Q44452165-5AC83F98-1990-42D8-BF1E-430A71518275

Q44452165-F8641140-83A4-4D38-8A9A-4997F9671012

P2860

Q44452165-011E5446-DC54-4ABB-A2D2-032A0419BB0B

Q44452165-1AA8355B-3793-4F18-BC79-6D7A0F2A88E1

Q44452165-1E5C1397-622B-4036-B7F4-4F22B10B793E

Q44452165-1F4F7E68-D209-4EBD-B381-B020CAC1C78D

Q44452165-29CC8A29-9767-4606-9E4E-CFD648102879

Q44452165-49AF2B11-4B83-4BE4-9ABB-16239C00172D

Q44452165-5E4D67DD-A8A2-4DDB-88F8-31FB1B7ECC39

Q44452165-6E5BCF03-F390-44F6-A7F0-6A82AFE6D510

Q44452165-75E13C58-05FA-4EDE-8372-D37C10B005CF

Q44452165-83BCE66A-C3DD-4205-8220-65F16146CF21

P2888

Q44452165-2BC29721-454B-4D71-9EC6-2C3AC75BAF67

P304

Q44452165-5ECD7BF3-9DFD-4240-9413-BCF603B385F6

P31

Q44452165-CB3155FD-1138-4DE9-9017-7A1036A69889

P356

Q44452165-CCFA3AFE-3A4E-499F-9921-B2F58E490A42

P433

Q44452165-FBC9E183-5A8C-4F23-A106-FBE8DF124EC1

P478

Q44452165-C2AEDB61-79FC-4A69-BB58-E56AE796E5F6

P50

Q44452165-3B4A202B-BBC0-4377-A661-D6E6732B6C81

P577

Q44452165-74B6B6F0-0710-4479-AD65-3EEC6850794D

P5875

Q44452165-0154FD8C-129F-4EDF-A24D-AE15C9681542

P698

Q44452165-9B3C4F79-67AA-4FD6-BD5D-AA68F714B050

P921

Q44452165-86221B5C-0813-4D95-8D07-52EA72E4C806

Q44452165-A5123D4B-FC2F-4B15-ABD9-75DFA316035B

P356

P1433

P1476

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

@en

P2093

Metelitsa LS

http://www.w3.org/2001/XMLSchema#string

Seeger RC

http://www.w3.org/2001/XMLSchema#string

Weinberg KI

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

CD1 recognition by mouse NK1+ T lymphocytes

NKT cells: facts, functions and fallacies.

Molecular biology of NK T cell specificity and development.

Gene expression in NKT cells: defining a functionally distinct CD1d-restricted T cell subset.

Natural killer T (NKT) cells and their role in antitumor immunity.

Control of myeloid dendritic cell differentiation and function by CD1d-restricted (NK) T cells.

Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers

Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining

P2888

P304

1068-1077

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2402943

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Peter D. Emanuel

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10746111

http://www.w3.org/2001/XMLSchema#string

P698

12764370

http://www.w3.org/2001/XMLSchema#string

P921